EPHB4 and squamous cell carcinoma: For example, a phase I dose-escalation study of sEphB4-HAS, a soluble fusion protein that binds and sequesters the ligand for EphB4, in combination with chemotherapy, cetuximab and radiotherapy is ongoing in squamous cell carcinoma of head and neck patients (NCT04091867).